SpliSense
Jerusalem, Israel· Est.
Israeli biotech delivering inhaled ASO medicines to treat genetic pulmonary diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli biotech delivering inhaled ASO medicines to treat genetic pulmonary diseases.
Pulmonary Diseases
Technology Platform
Proprietary antisense oligonucleotide design coupled with inhaled aerosol delivery to achieve localized, high‑efficacy treatment of genetic lung disorders.
Opportunities
Successful inhaled ASO trials could open a new therapeutic class for genetic lung diseases and attract large‑pharma partnerships.
Risk Factors
Clinical efficacy, manufacturing scale‑up, and regulatory acceptance of inhaled nucleic‑acid therapies remain uncertain.
Competitive Landscape
Differentiates from systemic ASO and small‑molecule inhaled drugs through localized delivery, but faces competition from gene‑editing and mRNA platforms targeting similar pulmonary indications.